Not all biomarkers are created equal: Separating clinical value from marketing noise

Why the biomarker count became a marketing number

Preventive health is a competitive space. Clinics and platforms compete for customers who are, understandably, trying to figure out which service gives them the most for their money. When the product is a blood panel, the most visible proxy for quality is the number of things being measured.

This creates a predictable incentive: inflate the list. Not necessarily with dubious tests, but with measurements that are cheap to add, sound credible, and don't require anyone to explain why they matter clinically.

The result is lists padded with items that most physicians would never order as part of a preventive screen. Some common tactics worth knowing:

Lifestyle inputs counted as biomarkers. Sleep quality, alcohol consumption, family history, and medication use are highly valuable clinical inputs also in the interpretation of test results – but they're things you report, not things a laboratory measures. Including them in a biomarker count is like counting "how you feel today" as a diagnostic test.

Redundant ratios. Many panels list LDL/HDL ratio, total cholesterol/LDL ratio, and sometimes additional derived scores alongside the underlying values they're calculated from. If a panel already measures LDL, HDL, and total cholesterol, the ratio adds no new information. You could calculate it yourself with a calculator. Counting it separately is a way of turning three measurements into five.

Biomarkers without clinical thresholds. Some markers are genuinely interesting to researchers but don't yet have validated reference ranges for asymptomatic adults. Testing them in a screening context produces a number that looks meaningful but has no reliable interpretation attached to it.

None of this is unique to one provider. It's a structural feature of a market where the number of biomarkers has become a proxy for quality.

What a clinically meaningful biomarker actually does

The test for a meaningful biomarker is straightforward: does the result change what a physician would recommend? If the answer is consistently no, it belongs in a research study, not a preventive screen.

A good blood panel in a preventive context is designed to accomplish several key objectives.. It establishes your metabolic baseline, like glucose, insulin sensitivity, liver enzymes, kidney function. It assesses cardiovascular risk through a lipid profile, but one that's complete enough to be actionable: LDL, HDL, triglycerides, and, for a fuller picture, ApoB, which tracks the number of atherogenic particles more precisely than LDL alone. It looks at inflammation through high-sensitivity CRP and potentially other inflammatory markers. It checks for nutritional deficiencies that are genuinely prevalent in Switzerland – vitamin D (given our latitude and the indoor nature of modern work), B12, ferritin – and that have clear, correctable consequences when low. And it includes hormonal markers relevant to your age and sex.

What it doesn't do is pad that list with inputs you gave verbally or redundant ratios that restate what's already in the panel without adding clinical meaning.

When ratios add value, and when they don't

Not all ratios are padding. The distinction matters, and it's worth understanding before you try to evaluate a panel.

Some ratios capture something that the individual underlying values don't communicate as clearly on their own. The TC/HDL ratio (total cholesterol divided by HDL) is a good example: it's a validated predictor of cardiovascular risk, recommended in the European Society of Cardiology guidelines as a secondary target alongside LDL-C, and physicians actively use it to stratify risk in clinical practice. The TG/HDL ratio (triglycerides divided by HDL) is another: a high value is associated with insulin resistance and metabolic syndrome, and adds meaningful context that neither triglycerides nor HDL alone provides as efficiently. Both are included in Ahead's panel because both change the clinical conversation in a specific way.

The tactics that don't add value are more specific than they might appear. The most common is simple inversion: a panel that lists both LDL/HDL and HDL/LDL is reporting the same relationship twice, just flipped. One number is the reciprocal of the other. Similarly, the atherogenic index of plasma (AIP) and the log-transformed TG/HDL molar ratio describe the same underlying signal through different arithmetic. Counting both as separate biomarkers is counting one measurement twice with extra steps. The total cholesterol/LDL ratio is another example: it's a mathematical consequence of two values already in the panel, with no additional predictive value established for asymptomatic adults.

A related tactic applies not to ratios but to stable markers. Lp(a) is a genuinely important biomarker. It's largely genetically determined, doesn't respond meaningfully to lifestyle change, and a high level significantly elevates lifetime cardiovascular risk. It's worth testing. But because Lp(a) is so stable over time, testing it multiple times across closely spaced check-ups adds little to no new information. One measurement, properly interpreted, is what matters.

The question to ask of any ratio or repeated marker: does it tell your physician something that isn't already in the panel? If not, it's padding.

The markers that actually matter for adults living in Switzerland

Adults face a specific set of risks worth addressing through preventive blood testing. Understanding the landscape helps you evaluate what a panel should cover.

Cardiovascular disease remains the leading cause of death in Switzerland, according to the Swiss Federal Statistical Office. A meaningful lipid panel for cardiovascular risk goes beyond total cholesterol and LDL. ApoB has emerged as a stronger predictor of cardiovascular events than LDL-C alone because it captures the concentration of all atherogenic particles, not just their cholesterol content. Lipoprotein(a) is another marker worth checking as it's largely genetic, doesn't respond to lifestyle change, but significantly elevates lifetime cardiovascular risk when elevated, and most people don't know their level until they test.

For metabolic health, fasting glucose alone may catch diabetes late. HbA1c tells you about average glucose over the past three months. Fasting insulin goes further still. It can reveal insulin resistance years before glucose rises to a clinically abnormal level. A meaningful metabolic screen should include all three.

Vitamin D deficiency is widespread in Switzerland. A 2018 Swiss Health Survey found that more than 40% of the adult population has insufficient vitamin D levels, driven by northern latitude and predominantly indoor lifestyles. Testing 25-OH vitamin D and treating the result has cleardownstream benefits for bone density, immune function, and mood.

Thyroid function (TSH, and free T3/T4 where indicated) affects energy, weight, mood, and cognitive function. Thyroid disorders, particularly subclinical hypothyroidism, are significantly more common in women and often go undiagnosed for years.

These are the markers with clinical weight. A panel that covers them thoroughly is more valuable than one that covers them plus 40 entries that tell you nothing new.

How to read a biomarker list critically

When you're evaluating a check-up package, these questions help cut through the noise:

Does the panel include reported inputs – sleep, family history, medications – in the count? Subtract those. They're questionnaire items.

Does it list ratios? Here the answer requires a little more judgment. Some ratios belong: TC/HDL and TG/HDL have established clinical thresholds and add genuine value beyond the underlying values. The problem is double-counting: panels that list both LDL/HDL and HDL/LDL (inverses of each other), or both AIP and the TG/HDL molar ratio (the same signal repackaged), or TC/LDL alongside the values it's derived from. If you spot pairs like these, count them as one.

Does it repeat stable markers across the same panel? Lp(a) is worth testing, but it's genetically determined and changes very little over time. If you checked it recently, it might not add much value to check it again.

Does it include markers with no established clinical reference range for asymptomatic adults? Flag those as research-grade, not screening-grade.

What remains is the effective panel. Compare that number and that content across providers. You'll often find that a "150 biomarker" package and a well-constructed "80 biomarker" package have essentially the same clinically actionable content, sometimes even less, once the questionnaire entries and redundant ratios are removed.

What Ahead measures, and why

The Ahead Advanced blood panel covers 80+ clinically validated biomarkers, chosen because each one meets the standard above: it has established reference ranges for adult populations, and a result outside those ranges leads to a clear clinical conversation.

The panel goes beyond what a standard Swiss GP check-up covers, which typically includes a basic metabolic profile and full blood count. Ahead adds ApoB for cardiovascular risk, fasting insulin for early metabolic dysfunction, detailed vitamin and micronutrient status, and comprehensive hormonal profiling tailored to your age and sex. Where ratios are included – TC/HDL and TG/HDL – they're there because they have independent clinical value, not because they inflate the count. And we allow members to add stable biomarkers, such as Lipoprotein(a), as add-ons.

Results are reviewed by Ahead's Swiss board-certified physicians, who contextualize your numbers rather than just flagging anomalies. The goal is a report that tells you what your results mean and what, if anything, warrants follow-up.

Ahead complements your GP rather than replacing them. Findings from your check-up, presented as a structured report, give your Hausarzt better information to work with at your next appointment.

Supplementary health insurers may cover part of the cost. KPT's supplementary insurance "Pulse" reimburses up to CHF 1,500 for Ahead Health services. Some insurers including CSS, AXA, Visana, and Atupri cover blood tests to varying degrees. It's worth checking your supplementary policy before booking. Ask us about a pro-forma invoice, and we’ll help you!

Conclusion

The number of biomarkers on a panel is not a measure of its quality. It's a measure of how many items someone chose to put on a list, some of which may add genuine clinical value, and some of which may be there because they're cheap, easy, and make the number bigger.

The right question isn't "how many biomarkers does this panel test?" It's "how many of these biomarkers will actually change something, like a recommendation, a follow-up, a decision?" A well-constructed panel of 80 markers that answers that question confidently is worth more than a padded list of 150, where half of them are self-reported, that mostly answers it with noise.

Finding something worth acting on early isn't a frightening outcome. It's the whole point.